A single rapamycin dose protects against late-stage experimental cerebral malaria via modulation of host immunity, endothelial activation and parasite sequestration

BACKGROUND: Maladaptive immune responses during cerebral malaria (CM) result in high mortality despite opportune anti-malarial chemotherapy. Rapamycin, an FDA-approved immunomodulator, protects against experimental cerebral malaria (ECM) in mice through effects on the host. However, the potential fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mejia, Pedro, Treviño-Villarreal, J. Humberto, Reynolds, Justin S., De Niz, Mariana, Thompson, Andrew, Marti, Matthias, Mitchell, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679345/
https://www.ncbi.nlm.nih.gov/pubmed/29121917
http://dx.doi.org/10.1186/s12936-017-2092-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679345/
https://www.ncbi.nlm.nih.gov/pubmed/29121917
http://dx.doi.org/10.1186/s12936-017-2092-5

Ejemplares similares